1. Home
  2. EXFY vs FATE Comparison

EXFY vs FATE Comparison

Compare EXFY & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$1.13

Market Cap

132.1M

Sector

Technology

ML Signal

HOLD

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

HOLD

Current Price

$1.76

Market Cap

125.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
FATE
Founded
2008
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
125.6M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
EXFY
FATE
Price
$1.13
$1.76
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$4.50
$4.10
AVG Volume (30 Days)
640.8K
2.9M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.88
EPS
N/A
N/A
Revenue
$142,101,000.00
$6,646,000.00
Revenue This Year
$0.42
N/A
Revenue Next Year
$0.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.06
N/A
52 Week Low
$0.69
$0.91
52 Week High
$2.55
$2.47

Technical Indicators

Market Signals
Indicator
EXFY
FATE
Relative Strength Index (RSI) 62.63 50.76
Support Level $0.76 $0.99
Resistance Level $1.16 $1.94
Average True Range (ATR) 0.07 0.24
MACD 0.01 -0.01
Stochastic Oscillator 79.34 42.97

Price Performance

Historical Comparison
EXFY
FATE

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: